All News

30 September 2011

Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid TumorsAntibodies

29 September 2011

Lpath Initiates Dosing of iSONEP in First of Two Proof-of-Concept TrialsAntibodies

29 September 2011

Children’s Oncology Group and Apeiron to Jointly Conduct Phase II Study in Neuroblastoma With hu14.18-IL2 (APN301)Antibodies

27 September 2011

Novartis receives approval in Japan for two innovative therapies, Gilenya in MS and Ilaris in CAPSAntibodies

26 September 2011

Roche’s investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancerAntibodies

26 September 2011

Abbott Japan and Eisai Submit Application in Japan for Additional Indication of Humira (adalimumab), a Fully Human Anti-TNF-± Monoclonal Antibody, for Inhibition of Structural Damage of Joints in Rheumatoid ArthritisAntibodies

26 September 2011

Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for BavituximabAntibodies

26 September 2011

REMICADE Receives FDA Approval as First Biologic Treatment for Pediatric Ulcerative ColitisAntibodies

26 September 2011

Impact of CATT Study Findings Evident in Significant Reported Changes in Prescribing of Genentech’s Avastin and Lucentis for the Treatment of Wet AMD According to a BioTrends ReportAntibodies

23 September 2011

Alexion Receives CHMP Positive Opinion for Soliris (eculizumab) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the European UnionAntibodies

23 September 2011

Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical TrialAntibodies

23 September 2011

ImmunoGen, Inc. Announces Submission of IND for Wholly Owned Product Candidate for Non-Hodgkin’s LymphomaAntibodies

22 September 2011

NovImmune initiates a Proof-of-Concept study in Primary Biliary Cirrhosis (PBC)Antibodies

21 September 2011

Theraclone Sciences Announces Initiation of Phase 1 Clinical Trial of TCN-032 for Influenza AAntibodies

21 September 2011

Glycotope Enrolls First Patients in Phase I Trial with TrasGEX, a Glycooptimized HER2 Biobetter AntibodyAntibodies

21 September 2011

Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA (abatacept)Antibodies

21 September 2011

New study finds rheumatoid arthritis (RA) patients preferred ergonomically designed Cimzia (certolizumab pegol) syringe to conventional prefilled syringeAntibodies

20 September 2011

Fresenius Biotech’s Removab receives approval for a shorter infusion time in treating malignant ascitesAntibodies

19 September 2011

Prolia (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of TreatmentAntibodies

19 September 2011

FDA Approves New Indications for Prolia (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation TherapyAntibodies

16 September 2011

Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood ArthritisAntibodies

15 September 2011

Phase 2 Study of Eculizumab (Soliris) in Patients with Severe and Refractory Generalized Myasthenia Gravis Presented at MGFA Annual MeetingAntibodies

14 September 2011

MorphoSys Announces Clinical Milestone in Cancer Antibody Program with Bayer HealthCare PharmaceuticalsAntibodies

13 September 2011

Teva Announces Additional Investment in CureTechAntibodies

13 September 2011

Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for CancerAntibodies

13 September 2011

Thallion Provides Update on Phase II SHIGATEC TrialAntibodies

13 September 2011

VGX-100 Identified as Potential New Therapy for Dry Eye DiseaseAntibodies

12 September 2011

Peregrine PS-Targeting Antibodies Show Broad Potential to Image Tumors and Assess Cancer Therapy ResponseAntibodies

12 September 2011

FDA Issues Complete Response Letter to Janssen Biotech, Inc. for SIMPONI Supplemental Biologics License ApplicationAntibodies

9 September 2011

Sucampo and Numab Sign Drug Discovery CollaborationAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Nectin-4-Targeted Immunotherapy Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

TL1A Inhibitor Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics